Identification

Name
Chlorambucil
Accession Number
DB00291  (APRD00115)
Type
Small Molecule
Groups
Approved
Description

A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)

Structure
Thumb
Synonyms
  • 4-(P-Bis(beta-chloroethyl)aminophenyl)butyric acid
  • 4-(p-bis(β-chloroethyl)aminophenyl)butyric acid
  • 4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid
  • Ambochlorin
  • CHLORAMBUCIL
  • Chloraminophen
  • gamma-[P-Di(2-chloroethyl)aminophenyl]butyric acid
  • N,N-Di-2-chloroethyl-gamma-P-aminophenylbutyric acid
  • N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid
  • Phenylbutyric Acid Nitrogen Mustard
  • γ-[p-di(2-chloroethyl)aminophenyl]butyric acid
External IDs
CB-1348 / NCI-3088 / NSC-3088
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LeukeranTablet, film coated2 mg/1OralAspen Global Inc.1985-02-13Not applicableUs
LeukeranTablet2 mgOralAspen Pharmacare Canada Inc.1957-12-31Not applicableCanada
International/Other Brands
Celkeran (Celon) / Chloraminophène (Techni-Pharma) / Leukeran
Categories
UNII
18D0SL7309
CAS number
305-03-3
Weight
Average: 304.212
Monoisotopic: 303.079284271
Chemical Formula
C14H19Cl2NO2
InChI Key
JCKYGMPEJWAADB-UHFFFAOYSA-N
InChI
InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
IUPAC Name
4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid
SMILES
OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl

Pharmacology

Indication

For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.

Structured Indications
Pharmacodynamics

Chlorambucil is an antineoplastic in the class of alkylating agents that is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

Mechanism of action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

TargetActionsOrganism
UDNA
cross-linking/alkylation
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

99%

Metabolism
Not Available
Route of elimination

Chlorambucil is extensively metabolized in the liver primarily to phenylacetic acid mustard. The pharmacokinetic data suggests that oral chlorambucil undergoes rapid gastrointestinal absorption and plasma clearance and that it is almost completely metabolized, having extremely low urinary excretion.

Half life

1.5 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Chlorambucil.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Chlorambucil.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Chlorambucil.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Chlorambucil.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Chlorambucil.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Chlorambucil.Approved
ClozapineThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Clozapine.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Chlorambucil.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Chlorambucil.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Chlorambucil.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Chlorambucil.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Chlorambucil.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Chlorambucil.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Chlorambucil.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Chlorambucil.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorambucil.Approved, Investigational
FingolimodChlorambucil may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Chlorambucil.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Chlorambucil.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Chlorambucil.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Chlorambucil.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Chlorambucil.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Chlorambucil.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Chlorambucil.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Chlorambucil.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Leflunomide.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Chlorambucil.Investigational, Withdrawn
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Chlorambucil.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Natalizumab.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Chlorambucil.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Chlorambucil.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorambucil.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Chlorambucil.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chlorambucil.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Chlorambucil.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Chlorambucil.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Chlorambucil.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Chlorambucil.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Chlorambucil.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Chlorambucil.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Chlorambucil.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Chlorambucil.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Chlorambucil.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Chlorambucil.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Chlorambucil.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Chlorambucil.Investigational
TofacitinibChlorambucil may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Chlorambucil.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Chlorambucil.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Chlorambucil.Approved
Food Interactions
  • Drink liberally.
  • Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use.
  • Food reduces bioavailability.
  • Take on an empty stomach.

References

Synthesis Reference

Phillips, A. P. and Mentha, J.W.; U.S.Patent 3,046,301; July 24, 1962; assigned to Burroughs Wellcome & Co. (U.S.A.) Inc.

US2944079
General References
  1. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 14;343(24):1750-7. [PubMed:11114313]
  2. Yang K, Tan J, Wu T: Alkylating agents for Waldenstrom's macroglobulinaemia. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006719. doi: 10.1002/14651858.CD006719.pub3. [PubMed:19160296]
  3. Foon KA, Hallek MJ: Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia. 2010 Mar;24(3):500-11. doi: 10.1038/leu.2009.266. Epub 2009 Dec 24. [PubMed:20033051]
External Links
Human Metabolome Database
HMDB14436
KEGG Drug
D00266
KEGG Compound
C06900
PubChem Compound
2708
PubChem Substance
46506842
ChemSpider
2607
BindingDB
50003677
ChEBI
28830
ChEMBL
CHEMBL515
Therapeutic Targets Database
DNC001110
PharmGKB
PA448926
HET
CBL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Chlorambucil
ATC Codes
L01AA02 — Chlorambucil
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
3csj
MSDS
Download (74.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)1
1RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedNot AvailableChronic Lymphocytic Leukaemia (CLL)1
1, 2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Active Not RecruitingTreatmentLymphoma, Mantle-Cell / Mantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentMALT Lymphoma1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)2
2CompletedTreatmentLeukaemia, Lymphoblastic1
2CompletedTreatmentLeukemia, Lymphocytic, Chronic1
2CompletedTreatmentLymphocytic Leukemia, Chronic2
2CompletedTreatmentMantle Cell Lymphoma (MCL)1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Unknown StatusTreatmentMalignant Lymphomas1
3Active Not RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / B-Cell Chronic Lymphocytic Leukemia (B-CLL)1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)3
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Small-Cell1
3Active Not RecruitingTreatmentLeukemia, Lymphocytic, Chronic1
3Active Not RecruitingTreatmentLymphocytic Leukemia, Chronic2
3Active Not RecruitingTreatmentLymphoma, Mucosa-Associated Lymphoid Tissue1
3CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
3CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
3CompletedTreatmentGlomerulonephritis, Membranous / Glomerulosclerosis, Focal Segmental1
3CompletedTreatmentLeukemias1
3CompletedTreatmentLymphocytic Leukemia, Chronic2
3CompletedTreatmentLymphoplasmacytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
3CompletedTreatmentMalignant Lymphomas2
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
3TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
3Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Neoplasms1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentMalignant Lymphomas3
3Unknown StatusTreatmentMalignant Neoplasm of Stomach1
4CompletedTreatmentLymphocytic Leukemia, Chronic2
4CompletedTreatmentUveitis1
Not AvailableRecruitingNot AvailableChronic Lymphocytic Leukaemia (CLL)1
Not AvailableUnknown StatusTreatmentMalignant Lymphomas2

Pharmacoeconomics

Manufacturers
  • Smithkline beecham corp dba glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
TabletOral2 mg
Tablet, film coatedOral2 mg/1
Prices
Unit descriptionCostUnit
Leukeran 2 mg tablet3.92USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)65 °CPhysProp
water solubility1.24E+004 mg/LNot Available
logP1.70HANSCH,C ET AL. (1995), pH 7.4
pKa5.75HANSCH,C & LEO,AJ (1987)
Predicted Properties
PropertyValueSource
Water Solubility0.0773 mg/mLALOGPS
logP3.81ALOGPS
logP3.94ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)4.46ChemAxon
pKa (Strongest Basic)1.72ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity79.68 m3·mol-1ChemAxon
Polarizability31.98 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9739
Blood Brain Barrier+0.7889
Caco-2 permeable+0.5734
P-glycoprotein substrateNon-substrate0.6721
P-glycoprotein inhibitor INon-inhibitor0.9394
P-glycoprotein inhibitor IINon-inhibitor0.9222
Renal organic cation transporterNon-inhibitor0.6185
CYP450 2C9 substrateNon-substrate0.7651
CYP450 2D6 substrateNon-substrate0.744
CYP450 3A4 substrateNon-substrate0.6044
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.909
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9576
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7851
BiodegradationNot ready biodegradable0.9378
Rat acute toxicity3.5709 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6531
hERG inhibition (predictor II)Non-inhibitor0.8609
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.25 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-2491000000-ddb7d5da8316562dba36
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0zfr-0519000000-1bca00472dfc8c30a465

Taxonomy

Description
This compound belongs to the class of organic compounds known as nitrogen mustard compounds. These are compounds having two beta-haloalkyl groups bound to a nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Nitrogen mustard compounds
Direct Parent
Nitrogen mustard compounds
Alternative Parents
Dialkylarylamines / Aniline and substituted anilines / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
show 1 more
Substituents
Aniline or substituted anilines / Dialkylarylamine / Tertiary aliphatic/aromatic amine / Nitrogen mustard / Monocyclic benzene moiety / Benzenoid / Amino acid or derivatives / Amino acid / Tertiary amine / Carboxylic acid derivative
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, monocarboxylic acid, organochlorine compound, aromatic amine, nitrogen mustard (CHEBI:28830)

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Unknown
Actions
Cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Begleiter A, Mowat M, Israels LG, Johnston JB: Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma. 1996 Oct;23(3-4):187-201. [PubMed:9031099]
  4. Kashiwazaki G, Bando T, Shinohara K, Minoshima M, Kumamoto H, Nishijima S, Sugiyama H: Alkylation of a human telomere sequence by heterotrimeric chlorambucil PI polyamide conjugates. Bioorg Med Chem. 2010 Apr 15;18(8):2887-93. doi: 10.1016/j.bmc.2010.03.011. Epub 2010 Mar 10. [PubMed:20350810]
  5. Bielawska A, Bielawski K, Muszynska A: Synthesis and biological evaluation of new cyclic amidine analogs of chlorambucil. Farmaco. 2004 Feb;59(2):111-7. [PubMed:14871502]
  6. Minoshima M, Bando T, Shinohara K, Sugiyama H: Molecular design of sequence specific DNA alkylating agents. Nucleic Acids Symp Ser (Oxf). 2009;(53):69-70. doi: 10.1093/nass/nrp035. [PubMed:19749264]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Parker LJ, Ciccone S, Italiano LC, Primavera A, Oakley AJ, Morton CJ, Hancock NC, Bello ML, Parker MW: The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44. doi: 10.1016/j.jmb.2008.04.066. Epub 2008 May 4. [PubMed:18511072]
  2. Zhang J, Lou YJ: Relationship between activation of microsomal glutathione S-transferase and metabolism behavior of chlorambucil. Pharmacol Res. 2003 Dec;48(6):623-30. [PubMed:14527828]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grutzner U, Hagenbuch B, Stieger B, Meier PJ, Beuers U, Kramer W, Wess G, Paumgartner G: Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology. 1997 Oct;113(4):1295-305. [PubMed:9322525]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33